• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Diversity Challenges Slow Enrollment of Moderna’s Late-Stage COVID-19 Vaccine Trial

Diversity Challenges Slow Enrollment of Moderna’s Late-Stage COVID-19 Vaccine Trial

October 12, 2020

Moderna has slowed enrollment of its phase 3 COVID-19 vaccine trial because it is experiencing challenges recruiting enough Black, Latino and Native American participants. The Cambridge, Mass.-based biotech company suggests this lack of diversity is preventing researchers from understanding how its COVID-19 vaccine candidate works in minority populations.

The late-stage 30,000-person study has been filled with mostly White volunteers, despite the fact that COVID-19 infects the Black community in the U.S. at almost three times the rate as the White community. Only around 7 percent of Moderna’s vaccine trial consists of Black Americans as of Sept. 17, and as of Oct. 2, 33 percent of participants are minorities, a company spokesperson said. To bolster enrollment of minorities in this trial, Moderna says it has teamed up with academic researchers who have established ties with organizations in minority communities.

A total of 17 of the 100 sites participating in Moderna’s COVID-19 vaccine trial are listed on the company’s website as active but not currently recruiting. The website does not list a reason why recruiting has halted at these sites. Spokespeople from Moderna have said this enrollment slowdown will not prevent the company from seeking an Emergency Use Authorization for its vaccine candidate in the U.S. in the last week of November, pending initial safety and efficacy results.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing